Incidence of herpes zoster, 1997–2002

Mullooly, John P.; Riedlinger, Karen; Chun, Colleen; Weinmann, Sheila; Houston, Heather

doi:10.1017/s095026880400281x

Cited by 149 publications

(87 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of the varicella vaccination program on incidence, morbidity, and mortality was also reported by other data sources (18,93,154). For data from four states collected between 1990 and 1994 and in 2005, the incidences of varicella declined by 85% (88).…”

Section: Postvaccine Epidemiologymentioning

confidence: 69%

“…For data from four states collected between 1990 and 1994 and in 2005, the incidences of varicella declined by 85% (88). In data from a health maintenance organization (HMO) collected between 1996 and 1999, the varicella incidence among children Յ18 years of age declined by 49.7%, with vaccination coverage of 73% among 2-year-old children (93). Finally, according to a Massachusetts phone survey study conducted between 1998 and 2003, the varicella incidence declined from 16.5 cases/1,000 individuals to 3.5 cases/ 1,000 individuals (79%) overall, with Ն66% decreases for all age groups except adults (27% decrease) (154).…”

Section: Postvaccine Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics

Schmid¹,

Jumaan

2010

Clin Microbiol Rev

113

View full text Add to dashboard Cite

SUMMARY The licensure and recommendation of varicella vaccine in the mid-1990s in the United States have led to dramatic declines in varicella incidence and varicella-related deaths and hospitalizations. Varicella outbreaks remain common and occur increasingly in highly vaccinated populations. Breakthrough varicella in vaccinated individuals is characteristically mild, typically with fewer lesions that frequently do not progress to a vesicular stage. As such, the laboratory diagnosis of varicella has grown increasingly important, particularly in outbreak settings. In this review the impact of varicella vaccine on varicella-zoster virus (VZV) disease, arising complications in the effective diagnosis and monitoring of VZV transmission, and the relative strengths and limitations of currently available laboratory diagnostic techniques are all addressed. Since disease symptoms often resolve in outbreak settings before suitable test specimens can be obtained, the need to develop new diagnostic approaches that rely on alternative patient samples is also discussed.

show abstract

Section: Postvaccine Epidemiologymentioning

confidence: 69%

Section: Postvaccine Epidemiologymentioning

confidence: 99%

Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics

Schmid¹,

Jumaan

2010

Clin Microbiol Rev

113

View full text Add to dashboard Cite

show abstract

“…The approval of a vaccine to prevent herpes zoster (HZ) and postherpetic neuralgia in adults (1-3) has rekindled interest in the epidemiology of HZ (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). In particular, reliable and reproducible rates of zoster occurrence and complications will be needed to assess the national impact of HZ vaccination.…”

mentioning

confidence: 99%

Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?

Yawn¹,

Wollan²,

Sauver³

2011

American Journal of Epidemiology

View full text Add to dashboard Cite

Accurate rates of herpes zoster incidence and complication have become of greater interest as studies have suggested an increasing temporal trend in incidence rates across all age groups and long-term follow-up studies of vaccine effectiveness are required by the Food and Drug Administration. This study compares the results obtained from the most commonly used method to obtain herpes zoster data (rates obtained from administrative data) with results obtained when administrative data are supplemented by medical record review. Administrative billing code data identified 1,959 cases of herpes zoster in Olmsted County, Minnesota, adults between January 1, 1996, and December 31, 2001. Of those 1,959 cases, 1,669 (85.2%) could be confirmed by medical record review, a decrease in incidence rate of 14.8%, resulting in a decrease of 0.61/1,000 person-years when adjusted to the US adult population. Complication rates were also significantly different between the 2 methods. It is not clear if the 15% decrease in incidence rates would be seen in every administrative data set or if the lack of confirmation of cases may be variable in both validity and reproducibility between data sets, making estimations in temporal trends and pre/post-vaccine rates difficult to compare across data resources.

show abstract

“…The incidence of HZ in the general population has been estimated to be between 0.3 and 0.4% annually in the United States, Canada, and Europe (6,9,22,37). The risk of developing HZ increases dramatically upon reaching 50 years of age, and this risk subsequently increases to a rate that approximates 1% per year by the age of 75 years (30,31,38).…”

mentioning

confidence: 99%

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

Gilderman¹,

Lawless²,

Nolen³

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

The vaccine Zostavax has been shown to prevent herpes zoster (HZ) and postherpetic neuralgia and is recommended for individuals >60 years of age. This study compared the safety and the immunogenicity of a refrigerator-stable formulation (Zostavax refrigerated) with those of the current formulation (Zostavax frozen) in subjects >50 years of age. Subjects with a negative history for HZ were randomized 1:1 to receive one dose of either formulation. Enrollment was stratified 1:2 by age (50 to 59 years and >60 years). Safety was evaluated for 28 days postvaccination. Varicella-zoster virus (VZV) antibody responses were measured by a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The primary endpoints were the VZV antibody geometric mean titer (GMT; day 28), the VZV antibody geometric mean rise (GMR; days 1 to 28), and the incidence of vaccine-related serious adverse experiences (AEs) over 28 days. The refrigerated (n ‫؍‬ 182) and frozen (n ‫؍‬ 185) formulations induced similar GMTs (727.4 and 834.4 gpELISA units/ml, respectively); the estimated GMT ratio (refrigerated formulation/frozen formulation) was 0.87 (95% confidence interval, 0.71 to 1.07). The GMRs were 2.6-and 2.9-fold, respectively. No vaccine-related serious AEs were reported in either group, and the safety profiles of the formulations were generally similar. The frequencies of injection-site AEs during follow-up were 35.6% and 46.4% in the refrigerated and the frozen formulation groups, respectively, and were generally mild. The frequencies of systemic AEs were similar in the two groups, and those of vaccine-related AEs were ϳ6% in both groups. The refrigerator-stable formulation of Zostavax has an acceptable safety profile and is as immunogenic as the frozen formulation; thus, the vaccine may be used in clinical settings where freezer availability is limited.Herpes zoster (HZ), also known as shingles, is an often serious condition associated with the reactivation of varicellazoster virus (VZV) in individuals who have been exposed to the virus earlier in life (11,12). After the initial infection, which manifests clinically as chickenpox, VZV can become latent and reside in the dorsal or cranial nerve ganglia. The reactivation of VZV as HZ is usually characterized by a unilateral, dermatomally distributed cutaneous rash.The incidence of HZ in the general population has been estimated to be between 0.3 and 0.4% annually in the United States, Canada, and Europe (6, 9, 22, 37). The risk of developing HZ increases dramatically upon reaching 50 years of age, and this risk subsequently increases to a rate that approximates 1% per year by the age of 75 years (30,31,38). The long-lasting pain associated with HZ, termed postherpetic neuralgia (PHN), is the most common complication and cause of morbidity from HZ in immunocompetent patients (12,17,29,36). Worldwide, the lifetime risk of developing HZ has recently been estimated to be close to 30% in the general population and can be as high as 50% in individuals who reach the age of 85 years (9,13,18). Ch...

show abstract

Incidence of herpes zoster, 1997–2002

Cited by 149 publications

References 20 publications

Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics

Impact of Varicella Vaccine on Varicella-Zoster Virus Dynamics

Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

Contact Info

Product

Resources

About